Compare Schlumberger NV (SLB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs GeneDx Holdings Corp — how do they compare? Schlumberger NV trades at $48.95 (market cap $72.69B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Schlumberger NV is far larger — about 36× GeneDx Holdings Corp's market cap, and Schlumberger NV pays a 2.41% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and GeneDx Holdings Corp for 19 Days on average.
| SLB | WGS | |
|---|---|---|
Market Cap | $72.69B | $2.02B |
Volume | 16,228,451 | 734,640 |
Sector | Energy | Health |
52-Week High | $60.10 | $167.51 |
52-Week Low | $31.72 | $34.51 |
Typical Hold Time | 99 Days | 19 Days |
Enterprise Value | $81.42B | $2.05B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $48.98, up 2.13% today, with strong analyst support (85% buy ratings) and a $64.58 consensus price target suggesting 32% upside. Recent contract wins in Saudi Arabia, Oman, and Mozambique expand revenue visibility, though technical indicators show bearish momentum. The company maintains solid profitability with 8.53% net margins and consistent earnings beats in recent quarters.
SLB's multi-year contracts provide stable revenue streams, but declining profit margins and bearish technicals present near-term headwinds. The stock offers value with reasonable valuation multiples (P/E 23.89) and dividend income, though energy sector volatility and execution risks on new projects require monitoring.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
